Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
To understand long-term outcomes in severe obesity, TRIUMPH-1 featured a prespecified, blinded extension to 104 weeks for 532 participants who had a baseline BMI of at least 35 kg/m and tolerated their assigned treatment
What the phase 3 retatrutide data now show The evidence picture has moved recently
Research Involving Human and Animals Rights This article does not contain any studies with human participants or animals performed by any of the authors
Positive and negative controls outcome As expected, the positive results confirmed that the use of GLP-1 RAs was associated with an increased incidence of nausea/vomiting (aHR, 1.21
However, new side effects can become known after a drug has been approved and used by more people
US$ 23.55
US$ 21.37
US$ 27.74
US$ 22.92
US$ 20.78
